Pulmonx is an interventional pulmonology company focused on life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide.
Pulmonx has developed Endobronchial Valve (EBV) Treatment, a non-surgical approach to treating emphysema which is designed to reduce the volume of the diseased region of the lung by blocking airflow. Likely responders to EBV therapy can be identified using the Chartis Pulmonary Assessment System, as recently demonstrated in the STELVIO study in the New England Journal of Medicine.
Over 10'000 patients have been treated with EBV treatment. Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide.